Free Trial
→ What the hell is going on? (From Porter & Company) (Ad)tc pixel
OTCMKTS:PBLA

Panbela Therapeutics Earnings Date & Estimates

Panbela Therapeutics logo
$0.0002 0.00 (0.00%)
As of 11/9/2026 11:09 AM Eastern

Panbela Therapeutics is estimated to report earnings on Friday, November 13, 2026.

Research:Profile

Upcoming Earnings Announcement

Announcement Date
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Panbela Therapeutics

Panbela Therapeutics is expected to post earnings of -$2,640.00 per share. Panbela Therapeutics last reported on August 13, 2024, posting -$1.47 per share and beating the -$2.07 consensus estimate. Panbela Therapeutics has beaten the consensus EPS estimate in 1 of its last 4 quarters.

Consensus Estimates

Consensus EPS
-$2,640.00

Recent Track Record

Last Reported
Q2 2024
Last Quarter EPS
-$1.47 (Beat by +$0.60)
EPS Beat Rate
1 of last 4 quarters

Prepare for the Earnings Call

Panbela Therapeutics Earnings FAQ

Panbela Therapeutics (OTCMKTS:PBLA) is estimated to report earnings on Friday, November 13, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Panbela Therapeutics to post earnings of -$2,640.00 per share for the quarter.

Panbela Therapeutics Earnings Headlines

Panbela Therapeutics (PBLA) Expected to Release Earnings on Friday
November 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31180699
PBLA - Panbela Therapeutics, Inc.
October 20, 2026  |  seekingalpha.comhttps://seekingalpha.com/symbol/PBLA
You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
November 10 at 1:00 AM  |  Behind the Markets (Ad)
Panbela Therapeutics Inc.
June 10, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/pbla/interactive-chart?gaa_sig=RYyMC8qS239Frut5XyDbZqS2SC9tphQSKnra4nwpwrSnkW4Z2ZMiEIB81YkkdlCNv9Th04z_djVI5z8SKjp6qw%3D%3D
Panbela Therapeutics Announces Q3 2024 Financial Results
November 16, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/panbela-therapeutics-announces-q3-2024-financial-results-1034022158
Panbela Therapeutics, Inc.: Panbela Provides Business Update and Reports Q3 2024 Financial Results
November 15, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-11/63827984-panbela-therapeutics-inc-panbela-provides-business-update-and-reports-q3-2024-financial-results-399.htm
See More Panbela Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Panbela Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Panbela Therapeutics and other key companies, straight to your email.

About Panbela Therapeutics

Panbela Therapeutics (OTCMKTS:PBLA) is a biotechnology company focused on developing novel therapies for cancer and other serious diseases. The company’s research has centered on treatments that target polyamine metabolism, a biological process associated with tumor growth and cancer progression.

Panbela’s lead investigational product has been ivospemin, formerly known as SBP-101, which has been studied in combination with standard treatments for pancreatic ductal adenocarcinoma and other solid tumors. The company has also pursued eflornithine-based programs, including combinations intended to support cancer treatment and prevention strategies.

Panbela’s programs have primarily been in clinical development and have been evaluated through research and clinical-trial activities in the United States. As an investigational biotechnology company, its product candidates have not represented approved commercial therapies unless separately authorized by applicable regulators.

View Panbela Therapeutics Profile
Earnings Tools